Unraveling the Potential Role of Probiotics in Ameliorating Hyperuricemia
),
(1) Department of Internal Medicine, Faculty of Medicine and Health Science, Krida Wacana Christian University, Jakarta, Indonesia
Corresponding Author
Abstract
Hyperuricemia has gained clinical interest due to emerging evidence of its association with various diseases, such as hypertension, diabetes mellitus, cardiovascular disease, chronic kidney disease, and fatty liver. Gut dysbiosis has been suggested to be linked to hyperuricemia, as the gastrointestinal tract is responsible for approximately one-third of the total human uric acid excretion. Alterations in gut microbiota composition have been observed in individuals with hyperuricemia.. Probiotics have regained popularity due to their beneficial health effects, and several studies have shown their potential as a dietary intervention for hyperuricemia. This review aims to examine the intestinal dysbiosis in individuals with hyperuricemia and explore the role of probiotics in ameliorating uric acid levels.
Keywords
References
Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: Mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):212.
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med. 2017;15(1):123.
Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta Med Indones. 2017;49(2):136.
Li D, Yuan S, Deng Y, Wang X, Wu S, Chen X, et al. The dysregulation of immune cells induced by uric acid: Mechanisms of inflammation associated with hyperuricemia and its complications. Front Immunol. 2023;14:1282890.
Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016;8(4):145-59.
Pierzynowska K, Deshpande A, Mosiichuk N, Terkeltaub R, Szczurek P, Salido E, et al. Oral treatment with an engineered uricase, ALLN-346, reduces hyperuricemia, and uricosuria in urate oxidase-deficient mice. Front Med. 2020;7:569215.
Wang ZL, Li YC, Liao WH, Huang J, Liu YP, Li ZY, et al. Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout. Front Cell Infect Microbiol. 2022;12:935723.
Wang J, Chen Y, Zhong H, Chen F, Regenstein J, Hu X, et al. The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies. Crit Rev Food Sci Nutr. 2022;62(14):3979-89.
Yuan X, Chen R, Zhang Y, Lin XQ, Yang XH. Altered gut microbiota in children with hyperuricemia. Front Endocrinol. 2022;13:848715.
Choi HK, McCormick N, Lu N, Rai SK, Yokose C, Zhang YQ. Population impact attributable to modifiable risk factors for hyperuricemia. Arthritis Rheumatol. 2020;72(1):157-65.
Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12(7):3167-81.
Wang Z, Li Y, Liao W, Huang J, Liu Y, Li Z, et al. Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout. Front Cell Infect Microbiol. 2022;12:935723.
Kang D, Ha S. Uric acid puzzle: Dual role as anti-oxidantand pro-oxidant. EBP. 2014;12(1):1.
Abdolmaleky HM, Zhou JR. Gut microbiota dysbiosis, oxidative stress, inflammation, and epigenetic alterations in metabolic diseases. Antioxidants. 2024;13(8):985.
Singh AK, Durairajan SSK, Iyaswamy A, Williams LL. Elucidating the role of gut microbiota dysbiosis in hyperuricemia and gout: Insights and therapeutic strategies. World J Gastroenterol. 2024;30(40):4404-10.
Brovold H, Lund T, Svistounov D, Solbu M, Jenssen T, Ytrehus K, et al. Crystallized but not soluble uric acid elicits pro-inflammatory response in short-term whole blood cultures from healthy men. Sci Rep. 2019;9(1):10513.
Lai J, Luo S, Hung L, Huang C, Lien S, Lin L, et al. Physiological concentrations of soluble uric acid are chondroprotective and anti-inflammatory. Sci Rep. 2017;7(1):2359.
Ma Q, Honarpisheh M, Li C, Sellmayr M, Lindenmeyer M, Böhland C, et al. Soluble uric acid is an intrinsic negative regulator of monocyte activation in monosodium urate crystal–induced tissue inflammation. J Immunol. 2020;205(3):789-800.
Narang RK, Dalbeth N. Pathophysiology of gout. Seminars in nephrology. 2020;40(6):550-63.
Liu X, Lv QL, Ren HY, Gao L, Zhao P, Yang XM, et al. The altered gut microbiota of high-purine-induced hyperuricemia rats and its correlation with hyperuricemia. PeerJ. 2020;8:e8664.
Han RS, Wang Z, Li YK, Ke LY, Li X, Li CG, et al. Gut microbiota Lactobacillus johnsonii alleviates hyperuricemia by modulating intestinal urate and gut microbiota-derived butyrate. Chin Med J.1-5.
Lu CL, Li L, Shi T, Li Y, Zhou YB. Alterations of gut microbiota during the development of a hyperuricemia rat model. Med Microecol. 2025;24:100120.
Lv Q, Xu D, Zhang X, Yang X, Zhao P, Cui X, et al. Association of hyperuricemia with immune disorders and intestinal barrier dysfunction. Front Physiol. 2020;11:524236.
Guo Z, Zhang JC, Wang ZL, Ang KY, Huang S, Hou QC, et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep. 2016;6(1):20602.
Han QQ, Ren QD, Guo X, Farag MA, Zhang YH, Zhang Q, et al. Punicalagin attenuates hyperuricemia via restoring hyperuricemia-induced renal and intestinal dysfunctions. J Adv Res. 2025;69:449-61.
Shao TJ, Shao L, Li HC, Xie ZJ, He ZX, Wen CP. Combined signature of the fecal microbiome and metabolome in patients with gout. Front Microbiol. 2017;8.
Yu Y, Liu Q, Li H, Wen C, He Z. Alterations of the gut microbiome associated with the treatment of hyperuricaemia in male rats. Front Microbiol. 2018;9:2233.
Lin S, Zhang T, Zhu L, Pang K, Lu S, Liao X, et al. Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota. J Genet Genomics. 2021;48(9):781-91.
Wang J, Chen Y, Zhong H, Chen F, Regenstein J, Hu XS, et al. The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies. Crit Rev Food Sci Nutr. 2022;62(14):3979-89.
Zhao HY, Chen XY, Zhang L, Meng FQ, Zhou LB, Pang XY, et al. Lacticaseibacillus rhamnosus Fmb14 prevents purine induced hyperuricemia and alleviate renal fibrosis through gut-kidney axis. Pharmacol Res. 2022;182:106350.
Wang L, Ye J. Commentary: Gut microbiota reduce the risk of hyperuricemia and gout in the human body. Acta Pharm Sin B. 2024;14(1):433-35.
Maftei NM, Raileanu CR, Balta AA, Ambrose L, Boev M, Marin DB, et al. The potential impact of probiotics on human health: An update on their health-promoting properties. Microorganisms. 2024;12(2):234.
Tian M, Zhu YY, Lu SY, Qin YL, Li XY, Wang T, et al. Clinical efficacy of probiotic supplementation in the treatment of knee osteoarthritis: A meta-analysis. Front Microbiol. 2025;16:1526690.
Dewi S, Usman SY, Darmawan G, Girawan D. Probiotics in ankylosing spondylitis: A possible potency. Indones J Gastroenterol Hepatol Endosc. 2020;20(3):184-88.
Zeng LT, Yu GP, Yang KL, Hao WS, Chen H. The improving effect and safety of probiotic supplements on patients with osteoporosis and osteopenia: A systematic review and meta-analysis of 10 randomized controlled trials. eCAM. 2021;2021(1):9924410.
Yuan YQ, Ji W, Lin ZG, Gan K. Benefits of probiotics in rheumatoid arthritis patients: A systematic review and meta analysis. Trop J Pharm Res. 2023;22(2):399-406.
Wang ZB, Xin SS, Ding LN, Ding WY, Hou YL, Liu CQ, et al. The potential role of probiotics in controlling overweight/obesity and associated metabolic parameters in adults: A systematic review and meta-analysis. eCAM. 2019;2019(1):3862971.
Wang QH, Wang Z, Pang BX, Zheng HJ, Cao ZM, Feng CP, et al. Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Front Endocrinol. 2022;13:1014670.
Wu Y, Ye Z, Feng P, Li R, Chen X, Tian X, et al. Limosilactobacillus fermentum JL-3 isolated from "Jiangshui" ameliorates hyperuricemia by degrading uric acid. Gut Microbes. 2021;13(1):1-18.
Wang YX, Li SW, Li X, Wang M, Huang B, Feng KL, et al. Association between prebiotic, probiotic consumption and hyperuricemia in U.S. adults: a cross-sectional study from NHANES 2011–2018. Front Nutr. 2025;12:1492708.
Zhao S, Feng P, Hu X, Cao W, Liu P, Han H, et al. Probiotic Limosilactobacillus fermentum GR-3 ameliorates human hyperuricemia via degrading and promoting excretion of uric acid. iScience. 2022;25(10):105-98.
Szulińska M, Łoniewski I, Van Hemert S, Sobieska M, Bogdański P. Dose-dependent effects of multispecies probiotic supplementation on the lipopolysaccharide (LPS) level and cardiometabolic profile in obese postmenopausal women: A 12-week randomized clinical trial. Nutrients. 2018;10(6):773.
Hu CH. Gut microbes: Regulating uric acid. eLife. 2024;13:e104493.
Huang JH, Li XP, Zhao JY, Qiao WC, Liu L, Chen LJ. Progress in understanding the mechanism by which probiotics alletivate hyperuricemia. Food Sci. 2023;44(23):282-9.
James A, Ke HM, Yao T, Wang YS. The role of probiotics in purine metabolism, hyperuricemia and gout: Mechanisms and interventions. Food Rev Int. 2023;39(1):261-77.
Article Metrics
Abstract View
: 210 times
Download : 375 times
DOI: 10.24871/2632025274-279
Refbacks
- There are currently no refbacks.
